title: Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis.
abstract: TNF inhibitors are being used in a rapidly expanding number of rheumatoid arthritis (RA) patients due to their effectiveness and acceptable safety profiles. To date, concerns regarding the adverse effects of TNF inhibitors have focused on infections, hematologic malignancies, and demyelinating disorders. Recently, the development of autoantibodies and other autoimmunity has been increasingly reported. Here, we describe a 36-year-old RA patient in whom organizing pneumonia and systemic lupus erythematosus were detected during etanercept treatment.
authors.affiliation: Department of Rheumatology, Hospital for Rheumatic Diseases, Hanyang University, Seoul 133-792, Korea.
authors.forename: Soo-Kyung
authors.initials: SK
authors.lastname: Cho
authors.forename: Il Hwan
authors.initials: IH
authors.lastname: Oh
authors.forename: Chan Kum
authors.initials: CK
authors.lastname: Park
authors.forename: Sang-Cheol
authors.initials: SC
authors.lastname: Bae
authors.forename: Yoon-Kyoung
authors.initials: YK
authors.lastname: Sung
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D018549:Cryptogenic Organizing Pneumonia / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept